Us Bancorp \De\ Zentalis Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$2.9 - $4.57 $1,815 - $2,860	-626 Reduced 62.04%	383 $1,000
Q2 2024 Aug 06, 2024	BUY	$4.09 - $16.13 $1,468 - $5,790	359 Added 55.23%	1,009 $4,000
Q1 2024 May 07, 2024	SELL	$10.83 - $16.49 $86 - $131	-8 Reduced 1.22%	650 $10,000
Q4 2023 Feb 09, 2024	SELL	$9.84 - $20.13 $2,253 - $4,609	-229 Reduced 25.82%	658 $9,000
Q2 2023 Aug 09, 2023	BUY	$17.41 - $30.05 $7,259 - $12,530	417 Added 88.72%	887 $25,000
Q1 2023 May 09, 2023	BUY	$16.14 - $24.94 $7,133 - $11,023	442 Added 1578.57%	470 $8,000
Q3 2022 Oct 27, 2022	SELL	$20.23 - $31.73 $25,247 - $39,599	-1,248 Reduced 97.81%	28 $1,000
Q2 2022 Aug 01, 2022	SELL	$17.91 - $52.25 $3,134 - $9,143	-175 Reduced 12.06%	1,276 $36,000
Q1 2022 May 11, 2022	BUY	$41.58 - $80.89 $47,733 - $92,861	1,148 Added 378.88%	1,451 $67,000
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $20,276 - $25,691	303 New	303 $25,000

147

65.4M

43.2K

21.7K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $101M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.